

## PATIENT HISTORY


An active 74-year-old female presented with advanced osteoarthritis (OA) of the right knee. She previously had a total knee arthroplasty (TKA) in 2012 on her left knee and reported worsening right knee pain over the last five years. Her pain was primarily localized to the medial aspect of the knee and was accompanied by stiffness, intermittent swelling, and occasional locking/catching. X-ray imaging revealed OA best characterized as Kellgren-Lawrence Grade 4. Previous therapies included icing, a nonsteroidal anti-inflammatory drug (NSAID) topical gel, ibuprofen, and exercises - all of which provided only minimal relief.

## INTERVENTION

Ascent™ is an injectable amniotic fluid allograft designed to protect, cushion, lubricate, and reduce inflammation in fluid environments, such as joints and tendons. Ascent is processed using the patent-pending Selectify™ process that selects key amniotic fluid components and preserves the allograft in a shelf-stable format. The physician administered a 15 mg dose of Ascent reconstituted with 1 cc of 0.9% sterile saline under ultrasound guidance. No immediate adverse reactions or complications were encountered and the patient was advised to avoid strenuous activities for 24 – 36 hours following the injection.

## RESULTS

The patient was asked to complete a Visual Analog Scale (VAS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) immediately prior to injection (baseline), at 1 month, 2 months, and 3 months after the Ascent injection. The patient saw immediate and sustained improvements in both VAS and KOOS over her baseline responses. VAS improved from a baseline of five to one at 1 month, two at 2 months, and one at 3 months after her Ascent injection. KOOS reporting showed improvements over baseline for every metric including pain, symptoms, average daily living, sports and recreation, and quality of life.



For more information, visit [stimlabs.com](http://stimlabs.com)